PMID- 22338552
OWN - NLM
STAT- MEDLINE
DCOM- 20120312
LR  - 20171116
IS  - 1128-3602 (Print)
IS  - 1128-3602 (Linking)
VI  - 16
IP  - 1
DP  - 2012 Jan
TI  - The prevalence of the metabolic syndrome and its impact on the left ventricular 
      systolic function in the patients with non-diabetic first ST elevation myocardial 
      infarction.
PG  - 90-5
AB  - OBJECTIVE: Metabolic syndrome (MS) is common among the patients with myocardial 
      infarction. The degree of the left ventricular systolic dysfunction is shown to 
      be associated with poor prognosis after myocardial infarction. The aim of this 
      study was to evaluate the prevalence of MS and its impact on the left ventricular 
      systolic function in non-diabetic patients suffering first ST elevation 
      myocardial infarction (STEMI). MATERIAL AND METHODS: This study was conducted 
      prospectively in three centers. We included patients presenting with non-diabetic 
      first acute STEMI. The systolic functions of the left ventricle were assessed 
      through the ejection fraction, the wall motion score index (WMSI) and tissue 
      Doppler myocardial S wave velocities. The diagnosis of MS was done based on the 
      Adult Treatment Panel III clinical definition of the MS. RESULTS: Among the 240 
      patients, 90 patients (37.5%) had MS but 150 patients (62.5%) were free of the 
      MS. The patients in the MS group were older and the prevalence was higher among 
      the females. Mean myocardial S wave velocities were significantly lower in the 
      patients with the MS in comparison to the patients without the MS (6.70 +/- 1.68 
      vs. 7.39 +/- 1.64; p < 0.01). LVEF and WMSI were similar in two groups. 
      CONCLUSIONS: MS was highly common in nondiabetic patients with acute STEMI and 
      left ventricular systolic function were more severely impaired in these patients. 
      Our observations suggest that more severely impaired left ventricular systolic 
      function after acute STEMI may contribute to the higher morbidity and mortality 
      seen in the patients with MS after acute STEMI.
FAU - Yazici, H U
AU  - Yazici HU
AD  - Department of Cardiology, Gazi University School of Medicine, Ankara, Turkey. 
      drhyazici@gmail.com
FAU - Poyraz, F
AU  - Poyraz F
FAU - Turfan, M
AU  - Turfan M
FAU - Sen, N
AU  - Sen N
FAU - Tavil, Y
AU  - Tavil Y
FAU - Tulmac, M
AU  - Tulmac M
FAU - Vatankulu, M A
AU  - Vatankulu MA
FAU - Aygul, N
AU  - Aygul N
FAU - Ozdogru, I
AU  - Ozdogru I
FAU - Abaci, A
AU  - Abaci A
LA  - eng
PT  - Journal Article
PL  - Italy
TA  - Eur Rev Med Pharmacol Sci
JT  - European review for medical and pharmacological sciences
JID - 9717360
RN  - 0 (Lipids)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Electrocardiography
MH  - Female
MH  - Humans
MH  - Lipids/blood
MH  - Male
MH  - Metabolic Syndrome/complications/*epidemiology/*physiopathology
MH  - Middle Aged
MH  - Myocardial Infarction/complications/diagnostic imaging/*physiopathology
MH  - Ultrasonography
MH  - Ventricular Dysfunction, Left/physiopathology
MH  - Ventricular Function, Left/*physiology
EDAT- 2012/02/18 06:00
MHDA- 2012/03/13 06:00
CRDT- 2012/02/18 06:00
PHST- 2012/02/18 06:00 [entrez]
PHST- 2012/02/18 06:00 [pubmed]
PHST- 2012/03/13 06:00 [medline]
PST - ppublish
SO  - Eur Rev Med Pharmacol Sci. 2012 Jan;16(1):90-5.